Or call us at 1-877-219-7770
Add Your Heading Text Here
About our program
Learn about support
available for you and your
patients
Madrigal Patient Support® offers a continuum of support for your office and your patients throughout the Rezdiffra® (resmetirom) treatment journey, including coverage and access support, financial support, and ongoing education and nursing support.
Financial assistance
Madrigal Patient Support is committed to helping eligible patients get started on Rezdiffra as quickly as possible. For eligible commercially insured patients, this means getting them started even as their coverage is being approved.
Here’s a brief overview of financial assistance options for eligible patients:
- Bridge Program: Covers your patient’s Rezdiffra prescription until insurance coverage is approved.* Eligible commercially
insured patients experiencing a delay or denial can begin treatment at no cost while a coverage determination is being made. - Non-Invasive Test Program: Provides support to help cover out-of-pocket costs associated with non-invasive testing.
- Copay Program: Offers copay savings for eligible commercially insured patients.
- Patient Assistance Program: Provides Rezdiffra at no cost for eligible patients.
*For eligible commercially insured patients only. Terms and conditions apply.
Treatment education and dedicated support
Prior authorization support and access education
Case Managers and Access Reimbursement Managers provide patient-specific access guidance and insights into the local payer landscape.
Our team helps you navigate insurance requirements, coordinate care, and address any access or reimbursement challenges that may arise throughout your patients’ treatment journey.
Medication adherence support
Nurse Navigators provide disease and treatment education and promote medication adherence to patients who are prescribed Rezdiffra. They offer telephone support and outreach based on your patient’s preferences.
Need support from an Access Reimbursement Manager (ARM)?
Access Reimbursement Managers (ARMs) are available to provide proactive education about the Rezdiffra fulfillment process, financial assistance options, payer policies, and Madrigal Patient Support.
After you complete this form, an ARM will connect with you within several business days.
Indication and Important Safety Information
Indication
Rezdiffra is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Limitation of Use: Avoid use in patients with decompensated cirrhosis.
WARNINGS AND PRECAUTIONS
Hepatotoxicity
Hepatotoxicity has been observed with the use of Rezdiffra. One patient developed substantial elevations of liver biochemistries that resolved when treatment was interrupted. Please see full Prescribing Information for more details on this specific case of Hepatotoxicity [see Warnings and Precautions (5.1)].
Monitor for elevations in liver tests, liver-related adverse reactions, and symptoms/signs of hepatotoxicity (eg, fatigue, nausea, vomiting, right upper quadrant pain or tenderness, jaundice, fever, rash, and/or eosinophilia [>5%]). If hepatotoxicity is suspected, discontinue Rezdiffra and monitor. If laboratory values return to baseline, weigh the potential risks against the benefits of restarting Rezdiffra. If laboratory values do not return to baseline, consider druginduced autoimmune-like hepatitis (DI-ALH) or autoimmune liver disease in the evaluation of elevations in liver tests.
Gallbladder-Related Adverse Reactions
Cholelithiasis, acute cholecystitis, and obstructive pancreatitis (gallstone) were observed more often in Rezdiffratreated patients than in placebo-treated patients. The exposure-adjusted incidence rates (EAIRs) for these events were
less than 1 per 100 person-years (PY) for all treatment arms. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated. If an acute gallbladder event is suspected, interrupt treatment until the event is resolved.
Drug Interaction with Certain Statins
An increase in exposure of atorvastatin, pravastatin, rosuvastatin, and simvastatin was observed when concomitantly administered with Rezdiffra, which may increase the risk of adverse reactions related to these drugs.
Dosage adjustment for certain statins is recommended. Monitor for statin-related adverse reactions including, but not limited to, elevation of liver tests, myopathy, and rhabdomyolysis.
ADVERSE REACTIONS
The most common adverse reactions with Rezdiffra (reported in ≥5% of patients and higher compared to placebo) are diarrhea, nausea, pruritus, vomiting, constipation, abdominal pain, and dizziness. Diarrhea and nausea were the most common causes of treatment discontinuation.
DRUG INTERACTIONS
Clinically Significant Interaction Effects of Strong or Moderate CYP2C8 Inhibitors on Rezdiffra
- Concomitant use with strong CYP2C8 inhibitors (eg, gemfibrozil) is not recommended. Reduce Rezdiffra dosage if used concomitantly with a moderate CYP2C8 inhibitor (eg, clopidogrel).
Clinically Significant Interactions Affecting Other Drugs
- Statins: Limit daily rosuvastatin and simvastatin dosage to 20 mg. Limit pravastatin and atorvastatin dosage to 40 mg.
- CYP2C8 Substrates: Monitor patients more frequently for substrate-related adverse reactions if Rezdiffra is coadministered with CYP2C8 substrates where minimal concentration changes may lead to serious adverse reactions.
USE IN SPECIFIC POPULATIONS
Pregnancy
There are no available data on Rezdiffra use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Report pregnancies to Madrigal Pharmaceuticals, Inc. Adverse Event Reporting line at 1-800-905-0324 and visit https://pregnancyregistry.madrigalpharma.com for information about a pregnancy safety study.
Lactation
There is no information regarding the presence of Rezdiffra in human or animal milk, the effects on the breast-fed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Rezdiffra and any potential adverse effects on the breastfed infant from Rezdiffra or from the underlying maternal condition.
Geriatric Use
Numerically higher incidence of adverse reactions have been observed in patients ≥65 years of age compared to younger adult patients.
Renal Impairment
The recommended dosage of Rezdiffra in patients with mild, moderate, or severe renal impairment is the same as in patients with normal kidney function.
Hepatic Impairment
Avoid use in patients with decompensated cirrhosis (consistent with moderate to severe hepatic impairment). Moderate or severe hepatic impairment (Child-Pugh Class B or C) may increase the risk of adverse reactions.
The safety and effectiveness of Rezdiffra have not been established in patients with cirrhosis.
Please see full Prescribing Information for Rezdiffra.